Brevan Howard Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Brevan Howard Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$948K	Buy	73,923 +58,721	+386%	+$748K	0.01%	930
2025 Q4	$137K	Sell	15,202 -48,952	-76%	-$674K	﹤0.01%	1650
2025 Q3	$1.11M	Buy	64,154 +42,057	+190%	+$518K	﹤0.01%	848
2025 Q2	$207K	Buy	+22,097	New	+$181K	﹤0.01%	1700
2025 Q1	–	Sell	-108,351	Closed	-$1.26M	–	1367
2024 Q4	$1.26M	Buy	108,351 +93,433	+626%	+$1.46M	0.01%	374
2024 Q3	$307K	Buy	+14,918	New	+$344K	﹤0.01%	849
2021 Q2	–	Sell	-36,788	Closed	-$2.95M	–	59
2021 Q1	$2.95M	Sell	36,788 -21,222	-37%	-$1.42M	0.43%	33
2020 Q4	$3.16M	Buy	+58,010	New	+$2.11M	0.63%	26

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brevan Howard Capital Management's NTLA Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Intellia Therapeutics (NTLA) stake by 386% in Q1 2026, buying an estimated $748K and bringing the position to 73,923 shares worth $948K. The position accounts for 0.01% of the portfolio, ranked #930.

Brevan Howard Capital Management first reported a position in NTLA in Q4 2020 and has held it in 8 quarters since. The position peaked at $3.16M in Q4 2020. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Brevan Howard Capital Management held 73,923 shares of Intellia Therapeutics worth $948K as of Q1 2026.
Brevan Howard Capital Management bought 58,721 Intellia Therapeutics shares in Q1 2026, an estimated $748K.
Intellia Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #930 holding.
Brevan Howard Capital Management first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 8 quarters since.
Brevan Howard Capital Management's Intellia Therapeutics position peaked at $3.16M in Q4 2020.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.